In the SINGLE‑AF trial, for the no‑anticoagulant arm, how long was temporary anticoagulation permitted around cardioversion or other invasive cardiac procedures, and what happened if anticoagulation exceeded this period—were patients still considered part of the no‑anticoagulant group?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

SINGLE-AF Trial Temporary Anticoagulation Protocol

I cannot provide specific details about the SINGLE-AF trial's temporary anticoagulation protocol because the evidence provided does not contain information about the SINGLE-AF trial itself. The studies you've shared focus on cardioversion guidelines, post-ablation anticoagulation strategies, and general periprocedural management—but none directly address the SINGLE-AF trial design or its specific protocol for temporary anticoagulation in the no-anticoagulant arm.

What the Available Evidence Shows About Temporary Anticoagulation

Based on standard cardioversion guidelines that would typically inform such trial designs:

Duration of Temporary Anticoagulation Around Cardioversion

For cardioversion procedures, anticoagulation is typically required for at least 4 weeks after the procedure 1. The 2019 AHA/ACC/HRS guidelines specify that for AF requiring immediate cardioversion, "anticoagulation should be initiated as soon as possible and continued for at least 4 weeks after cardioversion unless contraindicated" 1.

Standard Periprocedural Windows

  • Pre-cardioversion: Either 3 weeks of therapeutic anticoagulation OR TEE-guided approach with anticoagulation initiated before the procedure 1, 2
  • Post-cardioversion: Minimum 4 weeks of anticoagulation regardless of rhythm outcome 1
  • For AF <48 hours duration: Guidelines permit immediate cardioversion with variable anticoagulation recommendations based on CHA₂DS₂-VASc score 2

Critical Gap in Your Question

To answer your specific questions about the SINGLE-AF trial—including the exact duration allowed, what constituted protocol violation, and how patients were analyzed if they exceeded the permitted window—you would need to consult:

  • The SINGLE-AF trial protocol publication
  • The main trial results paper with detailed methods section
  • Supplementary materials describing per-protocol vs intention-to-treat analyses

Common Trial Design Approaches

In typical anticoagulation discontinuation trials, when temporary anticoagulation exceeds protocol-defined limits:

  • Intention-to-treat analysis: Patients remain in their originally assigned group regardless of protocol deviations
  • Per-protocol analysis: Patients who violate anticoagulation duration limits may be excluded from secondary analyses
  • Time-to-event censoring: Extended anticoagulation periods may result in censoring at the time of deviation

Without the actual SINGLE-AF trial documentation, I cannot definitively state their specific approach.

References

Related Questions

In a patient who has been arrhythmia‑free for at least 12 months after catheter ablation, has a CHA₂DS₂‑VASc score ≤3 (men ≥1, women ≥2) and no prior stroke or transient ischemic attack, can oral anticoagulation be safely discontinued, and what rhythm‑monitoring protocol should be employed?
What assessments and checks should be performed before initiating anticoagulant therapy in a patient?
When should apixaban be discontinued in a patient with atrial fibrillation who has undergone catheter ablation?
Should apixaban (Eliquis) be discontinued before a pacemaker insertion?
Should a patient receive full anticoagulation after AV nodal ablation, and what anticoagulant regimen and duration are recommended?
What is testicular NASP (Nuclear Autoantigenic Sperm Protein)?
What nutritional therapy is recommended for patients with Graves disease?
In a heart failure patient with elevated serum creatinine (eGFR ≥30 mL/min/1.73 m²), how should sacubitril/valsartan (angiotensin receptor‑neprilysin inhibitor) be initiated, titrated, and monitored?
Is it appropriate to refer a patient with a superficial cheek abscess the size of a ping‑pong ball to general surgery or dermatology for incision and drainage?
Why were patients meeting the exclusion criteria excluded from the study, and was direct oral anticoagulant (DOAC) therapy indicated for them?
What is the appropriate management for a patient who reports pain despite hydrocodone use, relies on THC (tetrahydrocannabinol) gummies for pain control, and consistently tests positive on urine drug screens?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.